ArticleEuropean journal of medical research2026
A novel mechanistic insight: BYHWD glycosides promote vascular endothelial repair via EPCs.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo explore the mechanism of glycosides from BYHWD promote EPCs repairing damaged vascular endothelium.
methodsA model of vascular intimal damage in rats and an aging model in EPCs were established. HE staining was carried out to examine the blood vessel intima; Elisa assays were employed to assess the levels of TC, TG, HDL-C, LDL-C, Col-1, MMP-9, and TIMP-1; frozen sections were utilized to detect the homing status of EPCs in vivo; western blot was used to detect the contents of eNOS, ITGβ3, ITGβ6, FAK, P-FAK, ERK1/2 and P-ERK1/2; the CCK-8 assay was used to evaluate the proliferation rate; the cell migration test was used to evaluate cell migration capabilities; and the tube formation test was used to determine the tube formation ability.
resultsBYHWD, glycosides, and EPCs are capable of ameliorating intimal thickening. They can increase the levels of eNOS, raise HDL levels, and reduce TG, TC, and LDL levels. Moreover, glycosides can promote the function of EPCs following vascular intimal damage. BYHWD and glycosides can decrease the rate of EPCs cell aging and increase the cell proliferation rate, migration ability, and tube-forming function in the aging model. BYHWD and glycosides can down regulate P-FAK, P-ERK, ITGβ3, ITGβ6, Col-1, and MMP-9, while up regulate TIMP-1 levels in the aging model. Additionally, glycosides can promote EPCs to change the levels of these proteins.
conclusionGlycosides promote EPC-mediated repair of damaged vascular endothelium through inhibiting the integrin/ECM via FAK/ERK pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.